Nanomaterials,
Journal Year:
2024,
Volume and Issue:
14(10), P. 823 - 823
Published: May 8, 2024
Understanding
both
the
physicochemical
and
biological
interactions
of
nanoparticles
is
mandatory
for
biomedical
application
nanomaterials.
By
binding
proteins,
acquire
new
surface
identities
in
fluids,
protein
corona.
Various
studies
have
revealed
dynamic
structure
nano–bio
The
proteins
not
only
imparts
to
fluids
but
also
significantly
influences
their
bioactivity,
stability,
targeting
specificity.
Interestingly,
recent
endeavors
been
undertaken
harness
potential
corona
instead
evading
its
presence.
Exploitation
this
‘protein–nanoparticle
alliance’
has
significant
change
field
nanomedicine.
Here,
we
present
a
thorough
examination
latest
research
on
corona,
encompassing
formation,
dynamics,
developments,
diverse
bioapplications.
Furthermore,
aim
explore
at
interface,
paving
way
innovative
strategies
advance
addressing
challenges
promises
controlling
review
provides
insights
into
evolving
landscape
highlights
emerging.
Pharmaceutics,
Journal Year:
2023,
Volume and Issue:
15(7), P. 1916 - 1916
Published: July 10, 2023
Artificial
intelligence
(AI)
has
emerged
as
a
powerful
tool
that
harnesses
anthropomorphic
knowledge
and
provides
expedited
solutions
to
complex
challenges.
Remarkable
advancements
in
AI
technology
machine
learning
present
transformative
opportunity
the
drug
discovery,
formulation,
testing
of
pharmaceutical
dosage
forms.
By
utilizing
algorithms
analyze
extensive
biological
data,
including
genomics
proteomics,
researchers
can
identify
disease-associated
targets
predict
their
interactions
with
potential
candidates.
This
enables
more
efficient
targeted
approach
thereby
increasing
likelihood
successful
approvals.
Furthermore,
contribute
reducing
development
costs
by
optimizing
research
processes.
Machine
assist
experimental
design
pharmacokinetics
toxicity
capability
prioritization
optimization
lead
compounds,
need
for
costly
animal
testing.
Personalized
medicine
approaches
be
facilitated
through
real-world
patient
leading
effective
treatment
outcomes
improved
adherence.
comprehensive
review
explores
wide-ranging
applications
delivery
form
designs,
process
optimization,
testing,
pharmacokinetics/pharmacodynamics
(PK/PD)
studies.
an
overview
various
AI-based
utilized
technology,
highlighting
benefits
drawbacks.
Nevertheless,
continued
investment
exploration
industry
offer
exciting
prospects
enhancing
processes
care.
Abstract
Nanoparticles
are
used
in
the
clinic
to
treat
cancer,
resolve
mineral
deficiencies,
image
tissues,
and
facilitate
vaccination.
As
a
modular
technology,
nanoparticles
combine
diagnostic
agents
or
therapeutics
(e.g.,
elements,
small
molecules,
biologics),
synthetic
materials
polymers),
biological
molecules
antibodies,
peptides,
lipids).
Leveraging
these
parameters,
can
be
designed
tuned
navigate
microenvironments,
negotiate
barriers,
deliver
specific
cells
tissues
body.
Recently,
with
Emergency
Use
Authorization
of
COVID‐19
lipid
nanoparticle
vaccines,
advantages
potential
as
delivery
vehicle
have
been
displayed
at
forefront
biotechnology.
Here,
we
provide
5‐year
status
update
on
our
original
“Nanoparticles
Clinic”
review
(also
2‐year
second
review)
by
discussing
recent
system
approvals,
highlighting
new
clinical
trials,
providing
an
previously
highlighted
trials.
Drug Delivery and Translational Research,
Journal Year:
2021,
Volume and Issue:
12(3), P. 500 - 525
Published: July 23, 2021
Abstract
The
field
of
nanomedicine
has
significantly
influenced
research
areas
such
as
drug
delivery,
diagnostics,
theranostics,
and
regenerative
medicine;
however,
the
further
development
this
will
face
significant
challenges
at
regulatory
level
if
related
guidance
remains
unclear
unconsolidated.
This
review
describes
those
features
pathways
crucial
to
clinical
translation
highlights
considerations
for
early-stage
product
development.
These
include
identifying
critical
quality
attributes
essential
activity
safety,
appropriate
analytical
methods
(physical,
chemical,
biological)
characterization,
important
process
parameters,
adequate
pre-clinical
models.
Additional
concerns
evaluation
batch-to-batch
consistency
regarding
scaling
up
that
ensure
a
successful
reproducible
manufacturing
process.
Furthermore,
we
advise
close
collaboration
with
agencies
from
early
stages
assure
an
aligned
position
accelerate
future
nanomedicines.
Graphical
abstract
International Journal of Pharmaceutics,
Journal Year:
2021,
Volume and Issue:
605, P. 120807 - 120807
Published: June 16, 2021
Nanomedicines
based
on
poly(lactic-co-glycolic
acid)
(PLGA)
carriers
offer
tremendous
opportunities
for
biomedical
research.
Although
several
PLGA-based
systems
have
already
been
approved
by
both
the
Food
and
Drug
Administration
(FDA)
European
Medicine
Agency
(EMA),
are
widely
used
in
clinics
treatment
or
diagnosis
of
diseases,
no
PLGA
nanomedicine
formulation
is
currently
available
global
market.
One
most
impeding
barriers
development
a
manufacturing
technique
that
allows
transfer
production
from
laboratory
to
an
industrial
scale
with
proper
characterization
quality
control
methods.
This
review
provides
comprehensive
overview
technologies
analysis
polymeric
nanomedicines
nanoparticles,
scale-up
challenges
hinder
their
applicability,
issues
associated
successful
translation
into
clinical
practice.
Small,
Journal Year:
2022,
Volume and Issue:
18(36)
Published: April 9, 2022
Abstract
Nanoparticles
(NPs)
have
attracted
tremendous
interest
in
drug
delivery
the
past
decades.
Microfluidics
offers
a
promising
strategy
for
making
NPs
due
to
its
capability
precisely
controlling
NP
properties.
The
recent
success
of
mRNA
vaccines
using
microfluidics
represents
big
milestone
microfluidic
pharmaceutical
applications,
and
rapid
scaling
up
demonstrates
feasibility
industrial‐scale
manufacturing.
This
article
provides
critical
review
progress
delivery.
First,
synthesis
organic
focusing
on
typical
methods
their
applications
popular
clinically
relevant
NPs,
such
as
liposomes,
lipid
polymer
well
mechanisms
are
summarized.
Then,
several
representative
inorganic
(e.g.,
silica,
metal,
metal
oxide,
quantum
dots),
hybrid
is
discussed.
Lastly,
various
presented.
Frontiers in Bioengineering and Biotechnology,
Journal Year:
2019,
Volume and Issue:
6
Published: Jan. 10, 2019
L-Asparaginase
(ASNase)
is
a
vital
component
of
the
first
line
treatment
acute
lymphoblastic
leukemia
(ALL),
an
aggressive
type
blood
cancer
expected
to
afflict
over
53,000
people
worldwide
by
2020,
and
has
recently
been
shown
have
potential
for
preventing
metastasis
from
solid
tumors
as
well.
The
ASNase
is,
however,
characterized
plethora
side
effects,
ranging
immune
reactions
severe
toxicity.
Consequently,
in
accordance
with
Quality-by-Design
(QbD)
principles,
ingenious
new
products
tailored
minimize
adverse
while
increasing
patient
survival
devised.
In
following
pages,
reader
invited
brief
discussion
on
most
recent
developments
this
field.
Firstly,
review
presents
outline
improvements
manufacturing
formulation
processes,
which
can
severely
influence
important
aspects
product
quality
profile,
such
contamination,
aggregation
enzymatic
activity.
Following,
advances
protein
engineering
applied
development
biobetter
ASNases
(i.e.
reduced
glutaminase
activity,
proteolysis
resistant
less
immunogenic)
using
techniques
site-directed
mutagenesis,
molecular
dynamics,
PEGylation,
PASylation
bioconjugation
are
discussed.
Afterwards,
attention
shifted
towards
nanomedicine
including
technologies
encapsulation
immobilization,
aim
at
improving
pharmacokinetics.
Besides
discussing
results
innovative
representative
academic
research,
provides
overview
already
available
market
or
latest
stages
development.
With
this,
intended
provide
background
current
underpin
discussions
target
profile
future
ASNase-based
pharmaceuticals.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Feb. 21, 2024
Abstract
Inflammation-associated
diseases
encompass
a
range
of
infectious
and
non-infectious
inflammatory
diseases,
which
continuously
pose
one
the
most
serious
threats
to
human
health,
attributed
factors
such
as
emergence
new
pathogens,
increasing
drug
resistance,
changes
in
living
environments
lifestyles,
aging
population.
Despite
rapid
advancements
mechanistic
research
development
for
these
current
treatments
often
have
limited
efficacy
notable
side
effects,
necessitating
more
effective
targeted
anti-inflammatory
therapies.
In
recent
years,
nanotechnology
has
provided
crucial
technological
support
prevention,
treatment,
detection
inflammation-associated
diseases.
Various
types
nanoparticles
(NPs)
play
significant
roles,
serving
vaccine
vehicles
enhance
immunogenicity
carriers
improve
targeting
bioavailability.
NPs
can
also
directly
combat
pathogens
inflammation.
addition,
facilitated
biosensors
pathogen
imaging
techniques
This
review
categorizes
characterizes
different
NPs,
summarizes
their
applications
It
discusses
challenges
associated
with
clinical
translation
this
field
explores
latest
developments
prospects.
conclusion,
opens
up
possibilities
comprehensive
management
Advanced Healthcare Materials,
Journal Year:
2021,
Volume and Issue:
11(7)
Published: Aug. 31, 2021
White
blood
cells
(WBCs)
are
immune
that
play
essential
roles
in
critical
diseases
including
cancers,
infections,
and
inflammatory
disorders.
Their
dynamic
diverse
functions
have
inspired
the
development
of
WBC
membrane-coated
nanoparticles
(denoted
"WBC-NPs"),
which
formed
by
fusing
plasma
membranes
WBCs,
such
as
macrophages,
neutrophils,
T
cells,
natural
killer
onto
synthetic
nanoparticle
cores.
Inheriting
entire
source
cell
antigens,
WBC-NPs
act
decoys
simulate
their
broad
biointerfacing
properties
with
intriguing
therapeutic
potentials.
Herein,
recent
medical
applications
focusing
on
four
areas,
carriers
for
drug
delivery,
countermeasures
biological
neutralization,
nanovaccines
modulation,
tools
isolation
circulating
tumor
fundamental
research
is
reviewed.
Overall,
studies
established
platform
versatile
nanotherapeutics
application
